Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 32%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is a highly attractive investment opportunity, with a strong technological differentiation and a potentially transformative TAM for its CGM systems in the T2NIT patient market. The recent CONNECT RCT results have only reinforced this potential, with significant A1c and TIR improvements across various treatment regimens, high CGM utilization rates, and potential for integration with non-insulin therapies. Additionally, the recent real-world analysis showed that DexCom's CGM may have a positive impact on reducing cardiovascular events in T2NIT patients, further expanding its potential market opportunity. However, risks do exist, including potential delays in new product releases and competition reducing DexCom's competitive advantage. Overall, the potential for growth and profitability make DexCom a strong choice for investors.

Bears say

DexCom is expected to face pricing headwinds in the near future, but its core growth story, attractive TAM and market dynamics, and top-tier management team make it an industry leader. Despite potential pricing challenges, the company has strong upside potential through non-intensive Type 2 adoption and the launch of new products and coverage expansions, as seen in their impressive margins and strong FCF performance. While the company's first quarter may have faced some controversy, their revenue and margins forecasts remain strong, leading to a reiteration of a Buy rating and a lowered price target of $75, reflecting a 4.7x multiple of their estimated 2027 sales.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 32% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.